Biomea Fusion, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-05: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-05 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-11 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-11 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-11 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-11 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-27 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-27 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Policies and Practices Related to the Grant of Certain Equity Awards From time to time, we award stock options to our employees, including the NEOs. Historically, we have awarded new-hire option grants on or soon after a new hire’s employment start date and periodic annual refresh employee option gr… | |
| 2026-04-27 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | From time to time, we award stock options to our employees, including the NEOs. Historically, we have awarded new-hire option grants on or soon after a new hire’s employment start date and periodic annual refresh employee option grants, which refresh grants are typically approved at a meeting of the… | |
| 2026-04-27 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-27 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-27 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-27 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | On March 26, 2025, the compensation committee awarded a stock option grant to Michael J.M. Hitchcock, Ph.D., one of our NEOs, during the period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, Form 10-K or Form 8-K that discloses MNPI, or… | |
| 2026-04-27 DEF 14A | Awards Close To MNPI Disclosure Table | 2025-01-01..2025-12-31 | As required by Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information relating to the stock option grant awarded to Dr. Hitchcock during the Designated Period occurring during fiscal year 2025. Name Grant Date Number of Securities Underlying the Award Exerci… | |
| 2026-04-27 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: MichaelJMHitchcockPhD | 2025-03-26 | Michael J.M. Hitchcock, Ph.D. |
| 2026-04-27 DEF 14A | Award Undrlyg Securities | Individual: MichaelJMHitchcockPhD | 2025-03-26 | 350,000 |
| 2026-04-27 DEF 14A | Award Exrc Price | Individual: MichaelJMHitchcockPhD | 2025-03-26 | 2.52 |
| 2026-04-27 DEF 14A | Award Grant Date Fair Value | Individual: MichaelJMHitchcockPhD | 2025-03-26 | $691.67K |
| 2026-04-27 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: MichaelJMHitchcockPhD | 2025-03-26 | -0.087 |
| 2026-03-24 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-24 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-04 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-04 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-04 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-04 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-08-05 10-Q | Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-05 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-05-05 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-05 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-05 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-05 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-04-28 DEF 14A | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-28 DEF 14A | Award Timing MNPI Disclosure | 2024-01-01..2024-12-31 | Policies and Practices Related to the Grant of Certain Equity Awards From time to time, we award stock options to our employees, including the named executive officers. Historically, we have awarded new-hire option grants on or soon after a new hire’s employment start date and periodic annual refres… | |
| 2025-04-28 DEF 14A | Award Timing Method | 2024-01-01..2024-12-31 | From time to time, we award stock options to our employees, including the named executive officers. Historically, we have awarded new-hire option grants on or soon after a new hire’s employment start date and periodic annual refresh employee option grants, which refresh grants are typically approved… | |
| 2025-04-28 DEF 14A | Award Timing Predetermined | 2024-01-01..2024-12-31 | No | |
| 2025-04-28 DEF 14A | Award Timing MNPI Considered | 2024-01-01..2024-12-31 | Yes | |
| 2025-04-28 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-01-01..2024-12-31 | No | |
| 2025-04-28 DEF 14A | Award Timing How MNPI Considered | 2024-01-01..2024-12-31 | During 2024, we did not grant any stock options, stock appreciation rights or similar option-like instruments to any of our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, Form 10-K or Form 8-K … | |
| 2025-03-31 10-K | Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-03-31 10-K | Insider Trading Policies Proc Adopted | 2024-10-01..2024-12-31 | Yes | |
| 2024-10-29 10-Q | Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-10-29 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-10-29 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-10-29 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-07-31 10-Q | Rule10b51Arr Adopted | 2024-04-01..2024-06-30 | No | |
| 2024-07-31 10-Q | Non Rule10b51Arr Adopted | 2024-04-01..2024-06-30 | No | |
| 2024-07-31 10-Q | Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No | |
| 2024-07-31 10-Q | Non Rule10b51Arr Terminated | 2024-04-01..2024-06-30 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |